Get the Stockscreener App
3.88
2.90%
0.09
Verastem Inc stock is traded at $3.88, with a volume of 49,279.
It is up +2.90% in the last 24 hours and up +9.24% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$3.79
Open:
$3.8
24h Volume:
49,279
Relative Volume:
0.06
Market Cap:
$167.79M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-0.8879
EPS:
-4.37
Net Cash Flow:
$-86.46M
1W Performance:
-5.57%
1M Performance:
+9.24%
6M Performance:
-67.66%
1Y Performance:
-37.90%
1-Day Range:
$3.79
$3.90
1-Week Range:
$3.71
$4.285
52-Week Range:
$2.10
$14.22
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| VSTM | 3.88 | 167.79M | 3.64M | -87.37M | -86.46M | -4.37 |
| VRTX | 447.79 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.25 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.72 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.74 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.50 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
KRAS Inhibitors Market Report 2034: Epidemiology Data, - openPR
Data-Based Insights About Verastem Inc (VSTM) - Stocks Register
OrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc Sha - GuruFocus.com
Alyeska Investment Group L.P.'s Strategic Acquisition of Veraste - GuruFocus.com
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Verastem, Inc. (NASDAQ:VSTM) Receives $14.57 Average PT from Analysts - MarketBeat
Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision - Investing.com India
Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision By Investing.com - Investing.com Canada
Stonepine Capital Management, LLC Increases Stake in Verastem Inc - GuruFocus.com
Such Is The Power Of Verastem Inc (NASDAQ: VSTM) - Stocks Register
Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World
Verastem CEO Paterson sells $3,118 in common stock - Investing.com
Verastem CEO Paterson sells $3,118 in common stock By Investing.com - Investing.com UK
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem: Q3 Earnings Snapshot - The Washington Post
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times
Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance
Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan
Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace
SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Verastem preps an NDA as the stock struggles - BioWorld Online
Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders
Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK
Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan
This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News
Verastem Inc (VSTM) stock: A year of ups and downs - US Post News
Verastem CFO sells shares worth $17 to cover tax obligations By Investing.com - Investing.com Canada
Verastem CFO sells shares worth $17 to cover tax obligations - Investing.com India
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - StockTitan
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Verastem whipsaws after updates for cancer drug combo - MSN
Taking the lead: Verastem Inc (VSTM) - SETE News
Guggenheim’s latest rating for VSTM stock - Knox Daily
Verastem Inc’s results are impressive - US Post News
Nantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Inc (VSTM) Stock: A Year of Decreases and Increases - The InvestChronicle
Guggenheim Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq
Nantahala Capital Management LLC Takes Position in Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):